ArticleFrontiers in oncology2026
Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999-2023.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digestive system malignant tumors (DSMTs) represent a major contributor to global cancer-related morbidity and mortality. With improving cancer survival, coexisting conditions and complications, including liver failure, have become increasingly relevant in mortality patterns among patients with DSMTs. However, population-level evidence on temporal trends and disparities in liver failure-related mortality remains limited. Methods: This population-based retrospective repeated cross-sectional study used data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Death records from 1999 to 2023 were analyzed among patients aged ≥45 years with DSMTs, defined by ICD-10 codes C15-C26. Liver failure was identified using ICD-10 code K72 under a multiple cause-of-death framework. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Analyses were stratified by sex, age group, race and ethnicity, urbanization level, Census region, and Health and Human Services (HHS) region. Results: From 1999 to 2023, a total of 82,796 liver failure-related deaths occurred among patients aged ≥45 years with DSMTs in the United States. Annual deaths declined from 4,131 in 1999 to 3,250 in 2023 (-21.33%). The AAMR decreased from 4.34 per 100,000 population (95% CI: 4.21-4.47) to 2.08 per 100,000 (95% CI: 2.01-2.15), corresponding to a significant overall decline (AAPC = -2.94%, 95% CI: -3.18 to -2.69). Although mortality declined across most subgroups, substantial heterogeneity persisted. Males consistently exhibited higher mortality than females, deaths were concentrated among older age groups, and liver failure-related deaths increased markedly among Hispanic individuals. Geographic analyses revealed pronounced regional variation, with attenuated declines or increasing trends in selected Census and HHS regions. Conclusions: Liver failure-related mortality among middle-aged and older patients with DSMTs in the United States has declined substantially over the past two decades. However, this improvement has slowed in recent years and remains uneven across populations and regions. These findings support continued attention to liver function monitoring, liver disease risk assessment, and targeted surveillance in high-risk populations and regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.